house Resolution No.181

Reps. Garrett, Brixie, Hood, Kennedy, Chirkun, Stone, Rabhi, Lasinski, Sowerby, Liberati, Cherry, Haadsma, Ellison, Garza, Tyrone Carter, Bolden, Hoadley, Sabo, Pohutsky, Robinson, Pagan, Manoogian, Kuppa, Brenda Carter, Hertel, Gay-Dagnogo, Cynthia Johnson, Hope, Wittenberg, Shannon, Clemente and Love offered the following resolution:

A resolution to urge the U.S. Food and Drug Administration to address the current shortage of critical, lifesaving drugs.

Whereas, Drug shortages have a devastating impact on patient care and public health by limiting access to vital drugs and increasing health care costs; and

Whereas, U.S. healthcare providers experienced 186 new drug shortages in 2018, a 27 percent increase from 2017, and the highest number of shortages in the previous five years. In the first half of 2019 alone, there were 282 drugs in active shortage in the United States; and

Whereas, Shortages in medicines have plagued the United States for many years. These include intravenous immunoglobulin (IVIG), a drug used to treat immune disorders; intravenous sodium bicarbonate, an inexpensive drug often used in critical care; the EpiPen injection for allergic reactions, and other important drugs; and

Whereas, A survey conducted by the Institute for Safe Medication Practices showed that most healthcare providers feel patient lives are often endangered because they cannot administer needed drugs or provide proper treatment due to drug shortages, forcing them to ration and conserve drugs and prioritize which patients receive available drugs first; and

Whereas, Drug shortages have led to adverse patient events including mortality, treatment changes, inferior treatment, and medication errors, which occur because the right drug is not available or because of dosing errors in the preparation or administration of alternative medications; and

Whereas, Drug shortages increase patient out-of-pocket expenses, and cost hospitals and health facilities at least $359 million per year in labor costs alone as they employ mitigation strategies; and

Whereas, Efforts by the Food and Drug Administration (FDA) to prevent and mitigate drug shortages have been insufficient. Despite the enactment of federal legislation in 2012 expanding the FDAs regulatory authority to address drug shortages, new and active shortages have reached their highest levels in almost five years; and

Whereas, It is crucial that the FDA expand its efforts to solve this public health crisis by working proactively with manufacturers and other stakeholders to prevent and mitigate drug shortages; now, therefore, be it

Resolved by the House of Representatives, That we urge the U.S. Food and Drug Administration to address the current shortage of critical, lifesaving drugs; and be it further

Resolved, That copies of this resolution be transmitted to the Commissioner of the U.S. Food and Drug Administration and the members of the Michigan congressional delegation.